COVID-19 Vaccination in Patients With Cancer and Patients Receiving HSCT or CAR-T Therapy: Immune Response, Real-World Effectiveness, and Implications for the Future

Overview

Journal J Infect Dis

Publisher Oxford University Press

Specialty Infectious Diseases

Date 2023 Aug 4

PMID 37539765

Authors

Victoria G Hall

Benjamin W Teh

Affiliations

Soon will be listed here.

Abstract

Patients with cancer demonstrate an increased vulnerability for infection and severe disease by SARS-CoV-2, the causative agent of COVID-19. Risk factors for severe COVID-19 include comorbidities, uncontrolled disease, and current line of treatment. Although COVID-19 vaccines have afforded some level of protection against infection and severe disease among patients with solid tumors and hematologic malignancies, decreased immunogenicity and real-world effectiveness have been observed among this population compared with healthy individuals. Characterizing and understanding the immune response to increasing doses or differing schedules of COVID-19 vaccines among patients with cancer is important to inform clinical and public health practices. In this article, we review SARS-CoV-2 susceptibility and immune responses to COVID-19 vaccination in patients with solid tumors, hematologic malignancies, and those receiving hematopoietic stem cell transplant or chimeric-antigen receptor T-cell therapy.

Citing Articles

Combined autologous hematopoietic stem cell transplantation and CD19 CAR T-cell therapy for relapsed/refractory diffuse large B-cell lymphoma with mutation: A case report.

Cai Z, Zou D, Ma Q, Sun W, Guo Y SAGE Open Med Case Rep. 2025; 13:2050313X241306236.

PMID: 40078172 PMC: 11898238. DOI: 10.1177/2050313X241306236.

Real-world assessment of immunogenicity in immunocompromised individuals following SARS-CoV-2 mRNA vaccination: a two-year follow-up of the prospective clinical trial COVAXID.

Chen P, Bergman P, Blennow O, Hansson L, Mielke S, Nowak P EBioMedicine. 2024; 109:105385.

PMID: 39395230 PMC: 11663764. DOI: 10.1016/j.ebiom.2024.105385.

Effectiveness of Paxlovid in the treatment of the SARS-CoV-2 Omicron variant infection in children with hematologic malignancies: a retrospective cohort study.

Deng X, Jiang Y, Chen W, Qin X, Chen J, Li H Transl Cancer Res. 2024; 13(8):4219-4230.

PMID: 39262461 PMC: 11384919. DOI: 10.21037/tcr-24-70.

Mannan-Decorated Lipid Calcium Phosphate Nanoparticle Vaccine Increased the Antitumor Immune Response by Modulating the Tumor Microenvironment.

Wu L, Yang L, Qian X, Hu W, Wang S, Yan J J Funct Biomater. 2024; 15(8).

PMID: 39194667 PMC: 11355305. DOI: 10.3390/jfb15080229.

COVID-19 vaccine updates for people under different conditions.

Huang Y, Wang W, Liu Y, Wang Z, Cao B Sci China Life Sci. 2024; 67(11):2323-2343.

PMID: 39083202 DOI: 10.1007/s11427-024-2643-1.

References

Yang W, Zhang D, Li Z, Zhang K . Predictors of poor serologic response to COVID-19 vaccine in patients with cancer: a systematic review and meta-analysis. Eur J Cancer. 2022; 172:41-50. PMC: 9160160. DOI: 10.1016/j.ejca.2022.05.031. View

Hall V, Ferreira V, Wood H, Ierullo M, Majchrzak-Kita B, Manguiat K . Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. 2022; 23(3):380-385. DOI: 10.1038/s41590-021-01126-6. View

Lee L, Cazier J, Angelis V, Arnold R, Bisht V, Campton N . COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020; 395(10241):1919-1926. PMC: 7255715. DOI: 10.1016/S0140-6736(20)31173-9. View

Abid M, Rubin M, Ledeboer N, Szabo A, Longo W, Mohan M . Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients. Cancer Cell. 2022; 40(4):340-342. PMC: 8864440. DOI: 10.1016/j.ccell.2022.02.010. View

Fendler A, Au L, Shepherd S, Byrne F, Cerrone M, Boos L . Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study. Nat Cancer. 2022; 2(12):1321-1337. DOI: 10.1038/s43018-021-00275-9. View

Einarsdottir S, Martner A, Waldenstrom J, Nicklasson M, Ringlander J, Arabpour M . Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity. Blood Adv. 2022; 6(9):2723-2730. PMC: 8923719. DOI: 10.1182/bloodadvances.2021006937. View

Debie Y, Van Audenaerde J, Vandamme T, Croes L, Teuwen L, Verbruggen L . Humoral and Cellular Immune Responses against SARS-CoV-2 after Third Dose BNT162b2 following Double-Dose Vaccination with BNT162b2 versus ChAdOx1 in Patients with Cancer. Clin Cancer Res. 2022; 29(3):635-646. DOI: 10.1158/1078-0432.CCR-22-2185. View

Ljungman P, de la Camara R, Mikulska M, Tridello G, Aguado B, Al Zahrani M . COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. Leukemia. 2021; 35(10):2885-2894. PMC: 8171362. DOI: 10.1038/s41375-021-01302-5. View

Luque-Paz D, Sesques P, Wallet F, Bachy E, Ader F . B-cell malignancies and COVID-19: a narrative review. Clin Microbiol Infect. 2022; 29(3):332-337. PMC: 9633106. DOI: 10.1016/j.cmi.2022.10.030. View

10.

Garcia-Suarez J, DE LA Cruz J, Cedillo A, Llamas P, Duarte R, Jimenez-Yuste V . Impact of hematologic malignancy and type of cancer therapy on COVID-19 severity and mortality: lessons from a large population-based registry study. J Hematol Oncol. 2020; 13(1):133. PMC: 7542567. DOI: 10.1186/s13045-020-00970-7. View

11.

Shem-Tov N, Yerushalmi R, Danylesko I, Litachevsky V, Levy I, Olmer L . Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in haematopoietic stem cell transplantation recipients. Br J Haematol. 2021; 196(4):884-891. PMC: 8652777. DOI: 10.1111/bjh.17918. View

12.

Ohm J, Carbone D . Immune dysfunction in cancer patients. Oncology (Williston Park). 2002; 16(1 Suppl 1):11-8. View

13.

Addeo A, Shah P, Bordry N, Hudson R, Albracht B, Di Marco M . Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer. Cancer Cell. 2021; 39(8):1091-1098.e2. PMC: 8218532. DOI: 10.1016/j.ccell.2021.06.009. View

14.

Bange E, Han N, Wileyto P, Kim J, Gouma S, Robinson J . CD8 T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021; 27(7):1280-1289. PMC: 8291091. DOI: 10.1038/s41591-021-01386-7. View

15.

Oosting S, van der Veldt A, GeurtsvanKessel C, Fehrmann R, van Binnendijk R, Dingemans A . mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial. Lancet Oncol. 2021; 22(12):1681-1691. PMC: 8577843. DOI: 10.1016/S1470-2045(21)00574-X. View

16.

Lee L, Ionescu M, Starkey T, Little M, Tilby M, Tripathy A . COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study. Eur J Cancer. 2022; 175:1-10. PMC: 9276646. DOI: 10.1016/j.ejca.2022.06.038. View

17.

Sharafeldin N, Bates B, Song Q, Madhira V, Yan Y, Dong S . Outcomes of COVID-19 in Patients With Cancer: Report From the National COVID Cohort Collaborative (N3C). J Clin Oncol. 2021; 39(20):2232-2246. PMC: 8260918. DOI: 10.1200/JCO.21.01074. View

18.

Shahzad M, Chaudhary S, Zafar M, Hassan M, Hussain A, Ali F . Impact of COVID-19 in hematopoietic stem cell transplant recipients: A systematic review and meta-analysis. Transpl Infect Dis. 2022; 24(2):e13792. DOI: 10.1111/tid.13792. View

19.

Liebers N, Speer C, Benning L, Bruch P, Kraemer I, Meissner J . Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients. Blood. 2021; 139(1):142-147. PMC: 8530768. DOI: 10.1182/blood.2021013445. View

20.

Yang L, Chai P, Yu J, Fan X . Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants. Cancer Biol Med. 2021; 18(1):298-307. PMC: 7877167. DOI: 10.20892/j.issn.2095-3941.2020.0559. View